Fig. 1From: Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case reportMonitoring of BCR-ABL1 levels (red) and cytogenetic response (green) during the different treatments of the patient. HSCT, haematopoietic stem cell transplant; DLI, donor lymphocyte infusionBack to article page